Glipacure 50mg Tablet contains Vildagliptin 50mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by enhancing the incretin system, thereby increasing insulin secretion and decreasing glucagon levels in a glucose-dependent manner. This dual action helps improve glycemic control without causing significant hypoglycemia. Glipacure is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The recommended dosage is typically 50mg twice daily, but it may be adjusted based on clinical response and tolerability. Common adverse effects include headache, dizziness, and gastrointestinal disturbances, while rare but serious side effects may involve pancreatitis and hypersensitivity reactions. Glipacure should be used cautiously in patients with renal impairment, and dose adjustments may be necessary. Regular monitoring of blood glucose levels and renal function is advised during therapy. This medication is not indicated for type 1 diabetes or diabetic ketoacidosis.